(CercleFinance.com) – Intrasense announces the regulatory submission of its Liflow® 1.0 solution (registered trademark of the Myra project), an oncological platform dedicated to the analysis of diagnostic imaging and cancer monitoring.
Liflow®, a platform to support the diagnosis and longitudinal monitoring of patients in oncology, provides radiologists with a set of clinical tools, addressing all dimensions of monitoring patients suffering from cancer.
Liflow® is positioned as a paradigm shift in software solutions in
oncology, with artificial intelligence algorithms integrated into a single tool, thus optimizing the power of technology in the service of medicine.
Liflow® provides significant interpretation comfort through a unified interface. With the automatic calculation of the evolution of lesions, Liflow® optimizes their detection and facilitates medical reporting.
The start of marketing of Liflow® is planned for 2024.